A more recent small-molecule Bcl-2 inhibitor, venclexta (ABT-199), which has been approved for acute myeloid leukemia and chronic lymphocytic leukemia, is being investigated for the treatment of multiple cancers including some solid tumors. The gene discussed is BCL2; the disease is cancer.